{"id":186702,"name":"BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY)","slug":"blood-cancer-united-formerly-reported-asthe-leukemia-and-lymphoma-society","state":"DC","country":"United States of America","description":"Non profit dedicated to funding blood cancer research.","totalSpending":1810000,"filings":35,"yearlySpending":[{"year":2018,"income":200000},{"year":2019,"income":350000},{"year":2020,"income":200000},{"year":2021,"income":200000},{"year":2022,"income":200000},{"year":2023,"income":200000},{"year":2024,"income":220000},{"year":2025,"income":240000}],"issues":[{"code":"MMM","display":"Medicare/Medicaid"},{"code":"PHA","display":"Pharmacy"},{"code":"BUD","display":"Budget/Appropriations"},{"code":"HCR","display":"Health Issues"},{"code":"TAX","display":"Taxation/Internal Revenue Code"}],"firms":["KOUNTOUPES DENHAM CARR & REID, LLC"],"lobbyists":["LORI DENHAM","JULIE CARR","ROSE SULLIVAN (LISTED IN ERROR)","MJ KENNY","DENISE NORTHRUP","MARY BEAL","LESLIE ZELENKO"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Health & Human Services, Dept of (HHS)","White House Office","Executive Office of the President (EOP)"],"sampleDescriptions":["Issues related to Medicare Part D as related to blood cancer beneficiaries.","Issues related to the cost of care and protecting patient access to blood cancer treatment.  Issues related to specialty drug tiers.","Issues related to blood cancer research funding included in H. R. 1625, the Consolidated Appropriations Act of 2018.","Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R.1409 the Cancer Drug Parity Act of","Issues related to Medicare Part D as related to blood cancer beneficiaries."]}